AI Terminal
LIFE SCIENCE REIT PLC
Board/Management Information • Jun 24, 2022
5353_rns_2022-06-24_72026b96-26d4-4622-a560-04462e9c6c42.html
Board/Management Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 1578Q
Life Science REIT PLC
24 June 2022
24 June 2022
LEI: 213800RG7JNX7K8F7525
Life Science REIT plc
("Life Science REIT" or the "Company")
Changes to Board Roles
Life Science REIT (AIM: LABS), the real estate investment trust focused on UK life science properties, is pleased to announce that Richard Howell, currently a non-executive Director of the Company, will take on the role of Senior Independent Director. The Company also confirms his appointment, further to the announcement on 3 May 2022, as Chair of the Audit and Risk Committee.
Both appointments are with effect from today. Richard Howell's biography is available on the Company's website at www.lifesciencereit.co.uk/about-us/board-of-directors/.
Enquiries:
| Link Company Matters Limited - Company Secretary | |
| [email protected] | |
| Ironstone Asset Management - Investment Adviser | |
| Simon Farnsworth | via Buchanan below |
| Panmure Gordon (UK) Limited - Nominated Adviser and Joint Corporate Broker | +44 20 7886 2500 |
| Atholl Tweedie / Sapna Shah / Philip Shields / Chloe Ponsonby | |
| Jefferies International Limited - Joint Corporate Broker | +44 20 7029 8000 |
| Tom Yeadon / Andrew Morris / Oliver Nott | |
| Buchanan - Financial PR | +44 20 7466 5000 |
| Mark Court / Henry Wilson / Verity Parker | |
| [email protected] |
Notes to editors
Life Science REIT plc is a property business focused solely on the UK's growing life science sector, specifically targeting opportunities in the "Golden Triangle" research and development hubs of Oxford, Cambridge and London St Pancras. The Company's intention is to become the property provider of choice for life science companies in the UK, whilst enabling shareholders to gain exposure to a specific growth sector.
The objective of the Company's investment policy is focused on capital growth, whilst also providing a growing level of income, by investing primarily in a diversified portfolio of properties that are leased, or intended to be leased, to occupiers operating in the life science sector in the UK.
Life Science REIT joined the AIM market of the London Stock Exchange on 19 November 2021, having raised £350 million in its IPO. Its shares trade under the ticker LABS.
Further information is available at https://lifesciencereit.co.uk
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BOAFIMBTMTATBRT